The other winner in this category included Cipla Med that took home the silver metal. The winners of the e4m MarTech India Awards were judged in three main categories - Technology Providers ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have started manufacturing key medicines for such diseases in the country.

MUMBAI/BENGALURU (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces for U.S. President Donald Trump's plans to ...

Umang Vohra to Nimura: "In the case of tariff barriers, generics companies are likely to be more selective, focusing on high-value opportunities including 'first to file'." The Managing Director ...

Rs 2,740 and Rs 2,720 New EV Policy slashes import duties from 110 per cent to 15 per cent Competition will increase from foreign players Buy Cipla futures with a stop loss at Rs 1,460 for targets of ...

The National Stock Exchange has decided to remove Berger Paints from the Futures & Options segment, effective April 25. Existing unexpired contracts for the expiry months of February, March, and ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional ...

Cipla has got final approval from the USFDA for New Drug Application (NDA) for its Nilotinib Capsules 50 mg, 150 mg and 200 mg respectively. Nilotinib is an FDA approved drug used for the ...

As of the last recorded data, the Nifty 50 closed at 22,959.50. This closing price reflects market performance and investor sentiment on that particular day. It is essential to consider various ...

Waaree Energies Ltd. has bagged an order for supply of 362.5 MWp of solar photovoltaic (PV) modules from one of the top Indian renewable power project developers. The announcement on Wednesday ...

Nifty pharma falls today, February 19: The three out of the major five losers in the Nifty 50 were pharmaceutical stocks. (Image: Freepik) The Pharma stocks took the back seat in the Nifty 50 on ...